Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
3.150
+0.010 (0.32%)
At close: Sep 15, 2025, 4:00 PM EDT
3.130
-0.020 (-0.63%)
After-hours: Sep 15, 2025, 7:58 PM EDT
Nuvation Bio Employees
Nuvation Bio had 220 employees as of December 31, 2024. The number of employees increased by 169 or 331.37% compared to the previous year.
Employees
220
Change (1Y)
169
Growth (1Y)
331.37%
Revenue / Employee
$65,250
Profits / Employee
-$922,264
Market Cap
1.08B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 220 | 169 | 331.37% |
| Dec 31, 2023 | 51 | -2 | -3.77% |
| Dec 31, 2022 | 53 | -11 | -17.19% |
| Dec 31, 2021 | 64 | 28 | 77.78% |
| Dec 31, 2020 | 36 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NUVB News
- 13 hours ago - Nuvation Bio: A Rare Gem In The Risky Biotech Space - Seeking Alpha
- 8 days ago - Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer - Business Wire
- 10 days ago - Top 2 Health Care Stocks That May Plunge This Month - Benzinga
- 18 days ago - Nuvation Bio: What To Expect From IBTROZI Launch? - Seeking Alpha
- 19 days ago - Nuvation Bio to Participate in Upcoming Investor Conferences - Business Wire
- 5 weeks ago - Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 5 weeks ago - Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses - Business Wire
- 7 weeks ago - Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 - Business Wire